Precision BioSciences, Inc.
DTIL · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 25.10M | 25.10M | -62.31M | -111.64M | -38.10 |
| 2023 FY | 48.73M | 48.73M | -43.74M | -61.32M | -15.96 |
| 2024 FY | 68.70M | 68.70M | -26.16M | 7.17M | 1.05 |
| 2025 FY | 34.26M | 34.26M | -52.15M | -45.72M | -3.56 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 238.17M | 177.74M | 189.58M | 24.96M | 60.43M |
| 2023 FY | 159.78M | 140.92M | 116.68M | 31.27M | 18.86M |
| 2024 FY | 136.39M | 80.00M | 85.90M | 30.05M | 56.39M |
| 2025 FY | 154.42M | 62.17M | 110.82M | 28.81M | 92.25M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -45.75M | -3.32M | -49.07M | — | 45.91M |
| 2023 FY | -84.11M | -2.28M | -86.39M | — | -72.90M |
| 2024 FY | -58.45M | -250.00K | -58.70M | — | -8.21M |
| 2025 FY | -65.84M | -85.00K | -65.93M | — | 28.69M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 104.60M | -60.02M | — | — | — |
| 2023 FY | 42.06M | -43.35M | — | — | — |
| 2024 FY | 26.03M | -29.82M | — | — | — |
| 2025 FY | 53.36M | -28.66M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 18.00K | 18.00K | -21.88M | -23.52M | -2.13 |
| 2025 Q3 | 13.00K | 13.00K | -20.67M | -21.77M | -1.84 |
| 2025 Q4 | 34.20M | 34.20M | 12.51M | 20.13M | 1.06 |
| 2026 Q1 | 10.84M | 10.84M | -9.08M | -18.44M | -0.75 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 108.93M | 74.87M | 62.24M | 29.45M | 34.05M |
| 2025 Q3 | 93.51M | 76.88M | 44.87M | 29.13M | 16.63M |
| 2025 Q4 | 154.42M | 62.17M | 110.82M | 28.81M | 92.25M |
| 2026 Q1 | 143.89M | 67.79M | 99.37M | 28.47M | 76.10M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -20.27M | -2.00K | -20.27M | — | -14.98M |
| 2025 Q3 | -15.27M | — | -15.27M | — | -17.37M |
| 2025 Q4 | -11.25M | -34.00K | -11.28M | — | 65.94M |
| 2026 Q1 | -11.94M | -18.00K | -11.96M | — | -11.31M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 46.39M | 13.60M | — | — | — |
| 2025 Q3 | 65.24M | 49.49M | — | — | — |
| 2025 Q4 | 79.25M | -2.76M | — | — | — |
| 2026 Q1 | 135.49M | 64.59M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |